Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited submitted the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
ALFA Filings
Every announcement, straight from the exchange
Every Accretion Pharmaceuticals other announcement announcement on NSE and BSE, newest first, each with its own page.
Time
7 announcements with these filters
Accretion Pharmaceuticals Limited submitted the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Accretion Pharmaceuticals Limited approved an alteration to its Memorandum of Association to expand its business objects. The Board also approved increased borrowing and investment limits subject to shareholder approval.
Accretion Pharmaceuticals Limited has provided the web link for shareholders to access its Annual Report for FY 2025-26 and the 3rd AGM notice.
Accretion Pharmaceuticals Limited submitted its annual Structured Digital Database (SDD) compliance certificate for the financial year ended March 31, 2026. The certificate, issued by M/s. Sakhiya & Co., confirms that the company maintains a non-tamperable digital database for tracking UPSI events in accordance with SEBI Insider Trading Regulations.
Accretion Pharmaceuticals Limited informed the National Stock Exchange that it does not fall under the 'Large Corporate' category for the financial year 2026–2027. Consequently, the specific disclosure and compliance requirements for debt security issuance by large entities under SEBI circulars are not applicable to the company.
Accretion Pharmaceuticals Limited informed the NSE that Regulation 27(2) regarding quarterly corporate governance reports is not applicable. As an SME-listed entity, the company is exempt under SEBI LODR Regulation 15(2)(b). A certificate from Sakhiya & Co confirms this non-applicability for the quarter ended March 31, 2026.
Accretion Pharmaceuticals Limited submitted its Regulation 74(5) compliance certificate for the quarter ended March 31, 2026. The certificate from RTA KFin Technologies confirms that all company shares are in dematerialized form and no rematerialization requests were received during the period.